{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:24:37Z","timestamp":1778261077092,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":569,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Type 2 diabetes (T2D) and heart failure (HF) frequently coexist, but whether clinical outcomes and treatment effects of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) vary in relation to background glucose-lowering therapy (GLT) in this population is uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>DELIVER randomized patients with HF and left ventricular ejection fraction (LVEF) &amp;gt;40% to dapagliflozin or placebo. The primary outcome was a composite of worsening HF (HF hospitalization or urgent HF visit) or cardiovascular death. In this pre-specified analysis of participants with T2D, treatment effects were assessed by number and class of background GLT(s). Of 3150 participants with T2D at baseline, 22.9% were on no GLT, 36.5% were treated with 1 GLT, and 40.6% with \u22652 GLTs. During follow-up (median: 2.3\u2009years), treatment benefits of dapagliflozin (vs. placebo) on the primary outcome were consistent irrespective of the number of background GLTs (0 GLTs: hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.50\u20131.00; 1 GLT: HR 1.04, 95% CI 0.80\u20131.34; \u22652 GLTs: HR 0.71, 95% CI 0.56\u20130.90; pinteraction\u2009=\u20090.59). Similar findings were observed among participants with (HR 0.73, 95% CI 0.59\u20130.92) and without background metformin use (HR 0.89, 95% CI 0.72\u20131.11; pinteraction\u2009=\u20090.22) and in participants with (HR 0.89, 95% CI 0.69\u20131.16) and without background insulin use (HR 0.78, 95% CI 0.65\u20130.95; pinteraction\u2009=\u20090.45). Dapagliflozin was well-tolerated irrespective of the number of background GLTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapagliflozin safely and consistently improved clinical outcomes among individuals with T2D and HF with LVEF &amp;gt;40% irrespective of the number and class of background GLTs, and the benefits were not influenced by concomitant metformin or insulin use. These data bolster contemporary guidelines supporting first-line SGLT2i among individuals with T2D and HF, irrespective of background GLT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3269","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T03:30:04Z","timestamp":1715743804000},"page":"1539-1548","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Dapagliflozin in Patients with Diabetes and Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Background Glucose-Lowering Therapy: A Pre-Specified Analysis of the DELIVER Trial"],"prefix":"10.1093","volume":"26","author":[{"given":"Mats Christian H\u00f8jbjerg","family":"Lassen","sequence":"first","affiliation":[{"name":"Department of Medicine, Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Department of Cardiology, Copenhagen University Hospital \u2013 Herlev and Gentofte , Copenhagen ,","place":["Denmark"]},{"name":"Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Ostrominski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Kulac","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pardeep","family":"Jhund","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute , Kansas City, MO ,","place":["USA"]},{"name":"University of Missouri-Kansas City , Kansas City, MO ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore, Duke\u2013National University of Singapore , Singapore ,","place":["Singapore"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba , C\u00f3rdoba ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Petersson","sequence":"additional","affiliation":[{"name":"AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2026010913060947400_ejhf3269-bib-0001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"2026010913060947400_ejhf3269-bib-0002","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010913060947400_ejhf3269-bib-0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913060947400_ejhf3269-bib-0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913060947400_ejhf3269-bib-0005","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc24-S006","article-title":"6. Glycemic goals and hypoglycemia: Standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2026010913060947400_ejhf3269-bib-0006","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.2337\/dc20-1402","article-title":"Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy","volume":"43","author":"Docherty","year":"2020","journal-title":"Diabetes Care"},{"key":"2026010913060947400_ejhf3269-bib-0007","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913060947400_ejhf3269-bib-0008","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913060947400_ejhf3269-bib-0009","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2026010913060947400_ejhf3269-bib-0010","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium","year":"2022","journal-title":"Lancet"},{"key":"2026010913060947400_ejhf3269-bib-0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026010913060947400_ejhf3269-bib-0012","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913060947400_ejhf3269-bib-0013","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/dom.13938","article-title":"Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?","volume":"22","author":"Inzucchi","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026010913060947400_ejhf3269-bib-0014","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: The DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913060947400_ejhf3269-bib-0015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913060947400_ejhf3269-bib-0016","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/HYPERTENSIONAHA.118.11728","article-title":"Role of insulin-mediated antinatriuresis in sodium homeostasis and hypertension","volume":"72","author":"Brands","year":"2018","journal-title":"Hypertension"},{"key":"2026010913060947400_ejhf3269-bib-0017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00252649","article-title":"The effect of insulin on renal sodium metabolism. A review with clinical implications","volume":"21","author":"DeFronzo","year":"1981","journal-title":"Diabetologia"},{"key":"2026010913060947400_ejhf3269-bib-0018","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"2026010913060947400_ejhf3269-bib-0019","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13300-018-0420-6","article-title":"Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk","volume":"9","author":"Goncalves","year":"2018","journal-title":"Diabetes Ther"},{"key":"2026010913060947400_ejhf3269-bib-0020","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"22","author":"Mantsiou","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026010913060947400_ejhf3269-bib-0021","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.120.047965","article-title":"Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy","volume":"143","author":"Dave","year":"2021","journal-title":"Circulation"},{"key":"2026010913060947400_ejhf3269-bib-0022","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cmet.2023.08.003","article-title":"A big STEP for treatment of heart failure with preserved ejection fraction","volume":"35","author":"Verma","year":"2023","journal-title":"Cell Metab"},{"key":"2026010913060947400_ejhf3269-bib-0023","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010913060947400_ejhf3269-bib-0024","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.jacc.2023.09.812","article-title":"Glucagon-like peptide-1 receptor agonists in heart failure: STEPping across the ejection fraction divide","volume":"82","author":"Vaduganathan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010913060947400_ejhf3269-bib-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2023","journal-title":"Am Heart J"},{"key":"2026010913060947400_ejhf3269-bib-0026","volume-title":"A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial. Identifier: NCT04847557","author":"ClinicalTrials.gov"},{"key":"2026010913060947400_ejhf3269-bib-0027","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/7\/1539\/65512305\/eurjhf_26_7_1539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/7\/1539\/65512305\/eurjhf_26_7_1539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:07:33Z","timestamp":1767982053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/7\/1539\/8328740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3269","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"2024-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}